Lantheus控股 LNTH 深 沪
等待开盘 07-03 09:30:00 美东时间
109.89
+0.930
+0.85%
华盛通- 最 高110.9999
- 今 开109.92
- 成交量 51.11万股
- 最 低 108.00
- 昨 收 108.96
- 总市值 71.55亿
- 52周最高 111.86
- 市盈率 静 32.20
- 换手率 0.78%
- 52周最低 47.25
- 委 比 49.25%
- 总股本 6510.61万
- 历史最高 126.8899
- 量 比 0.37
- 振 幅 2.75%
- 历史最低 1.76
- 每 手 1
- 风险率 16.02%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 康托·菲茨杰拉德大幅上调AMD、英特尔、迈威尔科技、美光、西部数据目标价！Applied、INIO、LFTO、Quantinuum获多家大行首予买入评级
今日重点评级关注：Evercore ISI集团：维持ProQR Therapeutics"跑赢大市"评级，目标价从5美元升至6美元；摩根士丹利：维持霍尼韦尔"标配"评级，目标价从245美元升至490美元
06-30 10:14
Lantheus Holdings Receives FDA Complete Response Letter For LNTH-2501 Due To Manufacturing Facility Issues; No Safety Or Efficacy Concerns Identified
Lantheus Holdings, Inc. ("Lantheus" or "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced today that the U.S. Food and Drug Administration (FDA) has issued a Comple...
06-27 04:02
Lantheus Receives Complete Response Letter from FDA for LNTH-2501 (Ga 68 edotreotide)
The U.S. FDA has issued a Complete Response Letter regarding Lantheus' NDA for LNTH-2501, a PET imaging kit for neuroendocrine tumors. The FDA cannot approve the NDA by June 29, 2026, due to unresolved manufacturing issues at a third-party facility. The agency did not identify concerns with the product's data, safety, or efficacy. Lantheus remains committed to resolving the manufacturing issues and advancing the product for patients.
06-26 20:01
Lantheus Holdings, Inc.收到Curium Pharma70亿美元收购要约，正推进谈判
经济观察网 全球核药巨头Lantheus Holdings, Inc.收到Curium Pharma的70亿美元收购要约，目前双方正处于讨论阶段，交易尚未最终敲...
06-05 03:10
美股大行评级 | 潜在涨幅99.91%！Tigress Financial上调英伟达目标价至425美元，维持"强力买入"评级
今日重点评级关注：Tigress Financial：维持英伟达"强力买入"评级，目标价从360美元升至425美元；康托·菲茨杰拉德：维持DeFi Development"超配"评级，目标价从6美元升至7美元
05-28 19:00
Mizuho Maintains Outperform on Lantheus Holdings, Raises Price Target to $115
Mizuho analyst Anthony Petrone maintains Lantheus Holdings (NASDAQ:LNTH) with a Outperform and raises the price target from $100 to $115.
05-27 22:09
BUZZ-$7 billion could be a 'light' price tag for Lantheus, Truist analysts say
BUZZ-$7 billion could be a 'light' price tag for Lantheus, Truist analysts say Nuclear medicine company Lantheus Holdings LNTH.O was weighing a potential sale, valuing it at about $7 bln , following a takeover offer from private-equity backed Curium Pharma, Bloomberg News reported on Friday ** A $7
05-26 17:57
'Lantheus Weighs Potential $7 Billion Sale Following Offer From Curium' - Bloomberg News
https://www.bloomberg.com/news/articles/2026-05-22/lantheus-is-said-to-weigh-sale-following-offer-from-curium
05-23 04:21
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
美股大行评级 | 爱彼迎、Affirm、CoreWeave、Datadog、微芯科技等获多家大行上调目标价；HubSpot惨遭14家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从15美元升至35美元；韦德布什：维持Cullinan Therapeutics"跑赢大市"评级，目标价从36美元升至37美元
05-11 15:43
